South & Central America Human Vaccine Adjuvants Market Forecast to 2030

South & Central America Human Vaccine Adjuvants Market Forecast to 2030

South & Central America Human Vaccine Adjuvants Market Forecast to 2030 – Regional Analysis – by Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), and End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others)

Send Enquiry
Item ID: BMIRE00030544 Category: Tag:

$2,485 – $3,885

Description

The South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030; it is estimated to register a CAGR of 14.3% from 2022 to 2030.

Rising Trend of Personalized Vaccines Fuels South & Central America Human Vaccine Adjuvants Market

Precision or personalized vaccines are a growing trend in the South & Central America human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient’s disease, assisting the production of vaccines tailored to each patient’s unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders. Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine’s specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can effectively increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone. Regulatory bodies and healthcare organizations recognize personalized vaccines’ potential for enhancing public health outcomes. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the South & Central America human vaccine adjuvants market.

South & Central America Human Vaccine Adjuvants Market Overview

Brazil is among the largest countries in South & Central America. According to the Brazilian Institute of Geography and Statistics (IBGE), Brazil has a unified healthcare system (SUS) that caters health services to approximately 72% of the population. SUS provides free medication and promotes national vaccination programs mostly focused on older adults and children. According to the International Trade Administration, Brazilian public laboratories and universities play a key role in research and development for diagnostic kits, drugs, and vaccines.

According to the Global Burden of Disease study published in October 2020, Brazil has an increasing prevalence of various chronic and infectious diseases, such as tuberculosis, stroke, influenza, chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and diabetes. Similarly, according to the CDC, mosquito-borne diseases (chikungunya, dengue, malaria, yellow fever, and Zika) are endemic in Brazil. Thus, the application of human vaccine adjuvants will increase due to the increasing disease burden in Brazil.

Rising healthcare expenditures and an increasing geriatric population are propelling the development of human vaccine adjuvants. According to the World Bank, Brazil’s healthcare expenditure was 10.31% of the GDP in 2020, a significant increase from 8.91% in 2015. Additionally, the rising geriatric population in the country is at high risk for various diseases and disabilities. The OECD reported that 21.9% of the population in Brazil is expected to be 65 years and above by 2050, a significant increase from 8.9% in 2017. Thus, the increasing geriatric population, infectious disease prevalence, and health expenditure would propel the growth of Brazil’s human vaccine adjuvants market in the coming years.

South & Central America Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Human Vaccine Adjuvants Market Segmentation

The South & Central America human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the South & Central America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the South & Central America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the South & Central America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the South & Central America human vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America human vaccine adjuvants market share in 2022.

Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp are some of the leading companies operating in the South & Central America human vaccine adjuvants market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

,

Year of Publication:

At 14.3% CAGR, South & Central America Human Vaccine Adjuvants Market is Speculated to be Worth US$ 185.34 Million by 2030, says the Research Team

According to the Research Team’ research, the South & Central America human vaccine adjuvants market was valued at US$ 63.62 million in 2022 and is expected to reach US$ 185.34 million by 2030, registering a CAGR of 14.3% from 2022 to 2030. Growing focus on immunization programs and rising trend of personalized vaccines are among the critical factors attributed to drive the South & Central America human vaccine adjuvants market growth.

Governments of various nations recognize the importance of vaccination as a cost-effective strategy to prevent and control chronic diseases. According to the WHO, immunization currently prevents 3.5-5 million deaths yearly from diseases such as diphtheria, tetanus, pertussis, influenza, and measles. As a result, governments in various nations are implementing immunization programs to reduce the incidence of diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. These programs often target specific populations, such as children, older people, and high-risk individuals, to ensure they are adequately protected against these chronic conditions. The United Nations International Children’s Emergency Fund (UNICEF) also offers an immunization program that provides vaccines to protect children from life-threatening diseases globally. In collaboration with member nations, Gavi (a vaccine alliance), UNICEF, and other global immunization partners, WHO launched “The Big Catch-up” in 2023, a global vaccination drive to support efforts to catch up, restore, and improve routine immunization globally. These campaigns aim to increase vaccination coverage rates and reduce the spread of infectious diseases that can exacerbate chronic conditions. As a result, there is a growing demand for vaccines and adjuvants that can enhance the immune response and provide long-lasting protection against these diseases. Thus, all these factors boost the growth of the South & Central America human vaccine adjuvants market.

On the contrary, the manufacturing complexities and regulatory challenges hampers the growth of South & Central America human vaccine adjuvants market.

Based on type, the South & Central America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held 39.5% market share in 2022, amassing US$ 25.07 million. It is projected to garner US$ 72.02 million by 2030 to register 14.1% CAGR during 2022-2030.

In terms of application, the South & Central America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held 37.6% share of South & Central America human vaccine adjuvants market in 2022, amassing US$ 23.92 million. It is anticipated to garner US$ 72.14 million by 2030 to expand at 14.8% CAGR during 2022-2030.

By end user, the South & Central America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held 48.7% share of South & Central America human vaccine adjuvants market in 2022, amassing US$ 30.95 million. It is projected to garner US$ 93.31 million by 2030 to expand at 14.8% CAGR from 2022 to 2030.

By country, the South & Central America human vaccine adjuvants market is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 53.0% share of South & Central America human vaccine adjuvants market in 2022. It was assessed at US$ 31.67 million in 2022 and is likely to hit US$ 95.05 million by 2030, registering a CAGR of 14.7% during 2022-2030.

Some of the key players operating in the South & Central America human vaccine adjuvants market are Novartis AG, CSL Ltd, Seppic SA, Croda International Plc, Novavax Inc, and Phibro Animal Health Corp, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America human vaccine adjuvants market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America human vaccine adjuvants market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
TABLE OF CONTENTS

1. Introduction
1.1 The the Reporting Teams Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Human Vaccine Adjuvants Market – Key Market Dynamics
4.1 South & Central America Human Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases
4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:
5. Human Vaccine Adjuvants Market – South & Central America Market Analysis
5.1 South & Central America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 – 2030
5.2 South & Central America Human Vaccine Adjuvants Market Forecast Analysis
6. South & Central America Human Vaccine Adjuvants Market Analysis – by Type
6.1 Particulate Adjuvant
6.1.1 Overview
6.1.2 Particulate Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
6.2.1 Overview
6.2.2 Emulsion Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
6.3.1 Overview
6.3.2 Combination Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Others
6.4.1 Overview
6.4.2 Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Human Vaccine Adjuvants Market Analysis – by Application
7.1 Influenza
7.1.1 Overview
7.1.2 Influenza: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
7.2.1 Overview
7.2.2 Hepatitis: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
7.3.1 Overview
7.3.2 Human papilloma virus (HPV): South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Human Vaccine Adjuvants Market Analysis – by End User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Overview
8.1.2 Pharmaceutical and Biotechnology Companies: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
8.2.1 Overview
8.2.2 CMOs and CROs: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Human Vaccine Adjuvants Market – Country Analysis
9.1 South & Central America
9.1.1 South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
9.1.1.1 Brazil Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Brazil Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.1.2 Brazil Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.1.3 Brazil Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.2 Argentina Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Argentina Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.2.2 Argentina Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.2.3 Argentina Human Vaccine Adjuvants Market Breakdown, by End User
9.1.1.3 Rest of South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Type
9.1.1.3.2 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Application
9.1.1.3.3 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by End User
10. Industry Landscape
10.1 Overview
11. Company Profiles
11.1 Novartis AG
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 CSL Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Seppic SA
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Croda International Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novavax Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Phibro Animal Health Corp
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
12. Appendix
12.1 About The the Reporting Teams
12.2 Glossary of Terms

LIST OF TABLES

Table 1. South & Central America Human Vaccine Adjuvants Market Segmentation
Table 2. South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Table 3. South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 4. South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Application
Table 5. South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 6. Brazil Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. Brazil Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 8. Brazil Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 9. Argentina Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 10. Argentina Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 11. Argentina Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 12. Rest of South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 13. Rest of South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 14. Rest of South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 15. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 16. Glossary of Terms, Human Vaccine Adjuvants Market

LIST OF FIGURES

Figure 1. South & Central America Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. South & Central America Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
Figure 4. South & Central America Human Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. South & Central America Human Vaccine Adjuvants Market Share (%) – by Application (2022 and 2030)
Figure 10. Influenza: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America Human Vaccine Adjuvants Market Share (%) – by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries – Revenue (2022) (US$ Million)
Figure 19. South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. Brazil Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 21. Argentina Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 22. Rest of South & Central America Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)

The List of Companies – South & Central America Human Vaccine Adjuvants Market

1. Novartis AG
2. CSL Ltd
3. Seppic SA
4. Croda International Plc
5. Novavax Inc
6. Phibro Animal Health Corp

Reviews

There are no reviews yet.

Be the first to review “South & Central America Human Vaccine Adjuvants Market Forecast to 2030”